1032824-91-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(Hydroxymethyl)Piperidine-1-Carbonitrile is utilized as an intermediate in the synthesis of various organic compounds and pharmaceutical ingredients. Its unique structure allows it to serve as a key component in the creation of new drugs, potentially contributing to advancements in medicinal chemistry.
Used in Drug Development:
As a versatile building block, 4-(Hydroxymethyl)Piperidine-1-Carbonitrile is employed in the development of new drugs, where its chemical properties can be harnessed to design molecules with specific therapeutic effects. 4-(Hydroxymethyl)Piperidine-1-Carbonitrile's potential applications in drug discovery are currently under investigation, with the aim of identifying its full range of capabilities and properties.
Used in Medicinal Chemistry Research:
4-(Hydroxymethyl)Piperidine-1-Carbonitrile is also used in research settings to explore its potential therapeutic properties. Scientists are interested in understanding how 4-(Hydroxymethyl)Piperidine-1-Carbonitrile interacts with biological systems and how it might be modified or combined with other molecules to produce novel medications.

Upstream product

• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 6457-49-4 4-piperidinemethanol 
• 172876-96-9 3-oxo-1λ³-benzo[d][1,2]iodaoxole-1(3H)-carbonitrile 
• 557-21-1 zinc(II) cyanide 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 90748-01-9 4-piperidinemethanol hydrochloride 
• 506-68-3 bromocyane 
• 498-94-2 isonipecotic acid 

Downstream Products

• 1351345-55-5 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351338-59-4 (3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-54-4 ((3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-57-2 (3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-53-3 ((3R,4S)-4-(4-chloro-2-fluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-52-7 ((3R,4S)-4-(4-chloro-2-fluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)amine 
• 1351345-52-2 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351338-51-6 (3R,4S)-1-{5-[l-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine 
• 1351345-51-1 ((3R,4S)-4-(2,4-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351345-80-6 C₃₁H₄₀F₂N₆O₄ 
• 1351343-45-7 ((3R,4S)-4-(2,5-difluoro-phenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methoxy-pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351342-38-5 [(3R,4S)-1-{5-[1-(3-ethyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351341-81-5 [(3R,4S)-4-(2,5-difluorophenyl)-1-(5-{[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethyl]amino}pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1032825-19-6 (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate 

Relevant academic research and scientific papers

N-Cyanation of Primary and Secondary Amines with Cyanobenzio-doxolone (CBX) Reagent

An efficient electrophilic N-cyanation of amines with a stable and less-toxic cyanobenziodoxole reagent towards the synthesis of cyanamides is disclosed. This synthetically practicable strategy allows the construction of a wide variety of cyanamides under very mild and simple conditions with a broad functional group compatibility, and showcases a huge potential in late-stage modification of complex molecules.

Synthesis of Cyanamides via a One-Pot Oxidation-Cyanation of Primary and Secondary Amines

An operationally simple oxidation-cyanation method for the synthesis of cyanamides is described. The procedure utilizes inexpensive and commercially available N-chlorosuccinimide and Zn(CN)2 as reagents to avoid direct handling of toxic cyanogen halides. It is demonstrated to be amenable for the cyanation of a variety of primary and secondary amines and aniline derivatives as well as a complex synthetic intermediate en route to verubecestat (MK-8931). Additionally, kinetic measurements and other control experiments are reported to shed light onto the mechanism of this cyanation reaction.

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.